Liver Transplantation News and Research RSS Feed - Liver Transplantation News and Research

Study finds that ambivalence is common among liver donor candidates

Study finds that ambivalence is common among liver donor candidates

Living donors are important to increasing the number of viable grafts for liver transplantation. A new study published in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, found that ambivalence is common among donor candidates. [More]
Liver injury caused by herbals and dietary supplements increases 20% in U.S. study group

Liver injury caused by herbals and dietary supplements increases 20% in U.S. study group

New research shows that liver injury caused by herbals and dietary supplements increased from 7% to 20% in a U.S. study group over a ten-year period. [More]
Research findings call for clinical testing of relevant drugs to prevent NASH

Research findings call for clinical testing of relevant drugs to prevent NASH

Non-alcoholic fatty liver disease (NAFLD) is a common affliction, affecting almost 30 percent of Americans, with a significant number suffering from its most severe form, called non-alcoholic steatohepatitis or NASH, which can lead to cirrhosis and liver cancer. In recent years, NASH has become the leading cause of liver transplantation. [More]
RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

Lynn E. Taylor, M.D., director of The Miriam Hospital's HIV/Viral Hepatitis Coinfection program, states in the July, 2014 Rhode Island Medical Journal special edition, "RI Defeats Hep C" that eliminating hepatitis c virus infection (hep c or HCV) is feasible, can provide economic benefits, enhance capacity to address other health challenges, and improve health care disparities. [More]
Many liver transplant patients want to be involved in the decision of whether to accept the organ

Many liver transplant patients want to be involved in the decision of whether to accept the organ

A novel study reveals that more than half of liver transplant patients want to be informed of donor risk at the time a liver is offered for transplantation. Nearly 80% of those patients want to be involved in the decision of whether or not to accept the organ according to findings published in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. [More]
Genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma

Genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma

Two genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma (iCCA), the second most common form of liver cancer, according to a research published in the July issue of the journal Nature. [More]
Antiviral therapy can reduce risk of liver cancer in patients with chronic hepatitis B infection

Antiviral therapy can reduce risk of liver cancer in patients with chronic hepatitis B infection

One of the most severe complications of hepatitis B is the development of liver cancer, which is responsible for approximately 745,000 deaths worldwide each year. [More]
U.S. Preventive Services Task Force recommends hepatitis B screening for high risk individuals

U.S. Preventive Services Task Force recommends hepatitis B screening for high risk individuals

A simple blood test can detect if a person is one of the two billion people worldwide infected with hepatitis B. And now the U.S. Preventive Services Task Force recommends that all teens and adults who are high risk for hepatitis B get screened for the infection. [More]
OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products. [More]
U.S. urges daily pill for those at risk of AIDS

U.S. urges daily pill for those at risk of AIDS

The recommendation could transform AIDS prevention from reliance on condoms to a regimen that relies on an antiretroviral drug. Meanwhile, a report analyzes the costs and benefits of treating prison inmates for hepatitis C and a study finds that nearly half of American adults take prescriptions. [More]
uEtG accurately detects alcohol consumption in liver transplant candidates and recipients

uEtG accurately detects alcohol consumption in liver transplant candidates and recipients

Researchers from Italy confirm that urinary ethyl glucuronide (uEtG) accurately detects alcohol consumption in liver transplant candidates and recipients. [More]
Perfusion system at room temperature preserves and improves metabolic function of donor livers

Perfusion system at room temperature preserves and improves metabolic function of donor livers

A system developed by investigators at the Massachusetts General Hospital (MGH) Center for Engineering in Medicine (CEM) and the MGH Transplant Center has the potential to increase both the supply and the quality of donor organs for liver transplantation. [More]
High-dose steroid therapy following surgery do not improve bile drainage among infants

High-dose steroid therapy following surgery do not improve bile drainage among infants

Among infants who underwent surgery to repair bile ducts that do not drain properly (biliary atresia), the administration of high-dose steroid therapy following surgery did not significantly improve bile drainage after 6 months, although a small clinical benefit could not be excluded, according to a study in the May 7 issue of JAMA, a theme issue on child health. [More]
High doses of steroids fail to improve outcomes in pediatric liver disease

High doses of steroids fail to improve outcomes in pediatric liver disease

A multi-center study concludes that treating infants with high doses of steroids fails to improve medical outcomes in the end-stage pediatric liver disease biliary atresia and leads to earlier onset of serious adverse events. [More]

Cedars-Sinai director honored for lifetime of achievement in field of liver transplantation

Andrew S. Klein MD, MBA, director of the Cedars-Sinai Comprehensive Transplant Center is being honored for a lifetime of achievement in the field of liver transplantation by the Los Angeles chapter of the American Liver Foundation. [More]

Studies provide insight on quality of kidney and liver transplantation

The quality of kidney and liver donations is fundamentally important for the longevity of transplants and the health of recipients. That’s why it’s critical to know which organs are suitable for transplantation, as well as to use techniques that preserve an organ’s function after donation. [More]

Stool color guide and free mobile app help diagnose liver-ravaging disorder in babies

Fecal color and consistency are well-known markers of digestive health in both children and adults, but paying attention to a newborn's shade of poop can be a decided lifesaver in babies born with the rare, liver-ravaging disorder biliary atresia, commonly heralded by white or clay-colored stool. [More]

New parents need to pay attention to baby’s poop color, say pediatric gastroenterologists

Fecal color and consistency are well-known markers of digestive health in both children and adults, but paying attention to a newborn’s shade of poop can be a decided lifesaver in babies born with the rare, liver-ravaging disorder biliary atresia, commonly heralded by white or clay-colored stool. [More]
New data focuses on different approaches to improve diagnosis and treatment of HCC

New data focuses on different approaches to improve diagnosis and treatment of HCC

Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC). [More]
Obeticholic acid meets primary composite endpoint in Phase III study

Obeticholic acid meets primary composite endpoint in Phase III study

Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC. [More]